Cerus Corporation (CERS) Covered Calls

Cerus Corporation is a biomedical products company focused on the field of blood transfusion safety. The firm’s primary product, the INTERCEPT Blood System, is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens, including viruses, bacteria, and parasites. By targeting platelets, plasma, and increasingly red blood cells, the company aims to establish a global standard for proactive blood safety and availability.

You can sell covered calls on Cerus Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CERS (prices last updated Fri 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Cerus Corporation is dedicated to safeguarding the global blood supply through its proprietary pathogen reduction technology. The centerpiece of its portfolio is the INTERCEPT Blood System, the only pathogen reduction system with both FDA approval and CE mark for both platelets and plasma. The system uses a specialized photochemical process to cross-link the DNA and RNA of pathogens, preventing them from replicating and causing infection while preserving the therapeutic function of the blood components.

The company’s revenue is primarily derived from the sale of disposable kits and the associated illumination devices used by blood centers. A significant recent growth driver is the INTERCEPT Fibrinogen Complex (IFC), a therapeutic product for treating massive hemorrhage that offers a longer shelf life and faster availability than traditional cryoprecipitate. In 2026, the firm reached a milestone of 20 million cumulative doses made available globally, supported by a major distribution agreement with Blood Centers of America (BCA).

Competitive Landscape

The blood safety market is characterized by high regulatory barriers and a shift toward proactive pathogen reduction rather than reactive testing. Cerus enjoys a significant first-mover advantage, as its INTERCEPT system is foundational technology for many major blood centers. While it faces competition from traditional testing companies and alternative blood treatment technologies, the company’s extensive patent portfolio and global regulatory approvals create substantial barriers to entry.

Publicly traded competitors that are optionable include:

1. Haemonetics Corporation: A leader in blood and plasma component collection and surgical blood salvage technologies.
2. Terumo Group (ADR: TRUMY): A major global player in medical technology that provides competitive blood management and transfusion products.
3. QuidelOrtho Corporation: A significant provider of diagnostic testing and blood screening solutions used in clinical and transfusion medicine.
4. STAAR Surgical Company: A specialized, small-cap medical device firm within the healthcare sector.

Strategic Outlook and Innovation

The strategic roadmap for 2026 is anchored by the expansion of the INTERCEPT system into the red blood cell (RBC) market, the largest segment of the transfusion market. The company is currently conducting pivotal studies with a data readout expected in late 2026. Furthermore, the firm recently launched the INT200, its next-generation LED-based illuminator, which offers a more efficient physical design and improved software interface to support global scaling.

Innovation at the firm is moving toward enhancing the utility of blood products in emergency medicine, such as pre-hospital settings. Additionally, the firm is pursuing geographic expansion into major markets like China and Japan through strategic joint ventures. These efforts, combined with a focus on reaching non-GAAP EBITDA profitability, are intended to transform the company into a diversified global leader in transfusion medicine.

Want more examples? CENX Covered Calls | CEVA Covered Calls